Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X and Evertrak Sign Letter of Intent to Advance Infrastructure-Linked Plastic Waste Reduction Credit Initiative19.5.2026 19:45:00 CEST | Press release
Proposed initiative would evaluate the potential generation of Verra-aligned Plastic Waste Reduction Credits for approximately 200,000 railroad ties made from recycled plastic currently installed across railroad infrastructure in North America. CALGARY, AB / ACCESS Newswire / May 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across compliance and voluntary environmental markets, today announced the signing of a Letter of Intent with Evertrak LLC ("Evertrak"), the leading manufacturer of Glass Fiber Reinforced Composite (GFRC) railroad ties made from recycled plastic, to explore an infrastructure-linked Plastic Waste Reduction Credit ("PWRC") initiative under Verra's Plastic Waste Reduction (PWR) Standard. Across North America, 20 million railroad ties made from wood are replaced annually. Approximately 4-6 million of those ties are less than 12 years old. Safe, resilient, and efficient railroad infrastr
AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform19.5.2026 16:00:00 CEST | Press release
Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation. SINGAPORE AND DUNDALK, IRELAND / ACCESS Newswire / May 19, 2026 / AP Technologies, a vertically integrated contract manufacturer of catheters and medical tubing, today announced the acquisition of Blueacre Technology, a Dundalk, Ireland specialist in laser micromachining and nitinol processing for the medical device industry. The acquisition establishes AP Technologies' first European operation in Ireland's medtech corridor, and extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices. Terms were not disclosed. Blueacre brings nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry, including femtosecond and picosecond laser cutting, laser we
Business Leaders Still Primarily Use AI for Simple Tasks, Study from General Assembly and EZRA Finds19.5.2026 15:00:00 CEST | Press release
Those who have received leadership-specific AI training more likely to use AI more often and more strategically NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / A new survey of more than 500 U.S. and U.K. business leaders found that while they are increasingly confident in their own AI skills, the most common use cases of the technology at the leadership level remain simple tasks like searching for information (69%), summarizing documents (68%) and drafting emails (58%). Strategic applications such as scenario planning (27%), organizational design (27%) and financial modeling (28%) lag far behind. The research was conducted by General Assembly, a global leader in practical AI skills training, in collaboration with EZRA, a leading global coaching and learning provider, both LHH brands. The study also surfaces a sharp divide between leadership levels. Vice presidents consistently fall behind director-level colleagues across nearly every measure of AI adoption and competence, emerging
Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption19.5.2026 14:50:00 CEST | Press release
Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe COPENHAGEN, DK / ACCESS Newswire / May 19, 2026 / Black Book Research today issued a new European hospital cybersecurity advisory identifying the countries, attack surfaces, vendor categories, and evaluation standards now shaping hospital cybersecurity buying decisions across Europe. The advisory builds on Black Book's Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey of 284 self-identified European hospital, health system, HIT, clinical-digital, cybersecurity, procurement, risk, and executive respondents seeking cybersecurity options around HIMSS26 Europe in Copenhagen. Black Book reports that European hospital cybersecurity has moved beyond breach response. The 2026 priority is now clinical availability: protecting EHRs, EPRs, identity systems, lab platforms, pharm
AI Trading Bots Revolutionise Stock, Gold, and Forex Trading: Funds Coin Leads the Move with Guaranteed Profit Option Strategy19.5.2026 14:00:00 CEST | Press release
DENVER, CO / ACCESS Newswire / May 19, 2026 / Forex has always been the world's largest digital financial market in 2026. Now it has become entirely a 24-hour, data-saturated environment. According to the Bank for International Settlements, global OTC foreign exchange turnover reached $9.6 trillion per day in April 2025. This means the foreign exchange turnover was up 28% from 2022. This is a figure that underscores just how deeply connected forex is to global liquidity, risk management, and capital flows. Inside that volume, the competition has intensified dramatically. In 2026, retail traders are no longer competing mainly against other individuals; they are competing against automated systems, and AI-assisted execution engines like Funds Coin. The platform operates across stocks, forex, and financial markets simultaneously. Manual trading, in this environment, is not just inefficient. It is structurally outpaced. Why AI Bots Are Taking Over Forex The following table is provided for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom